Terms ending in 2033
Every in-force patent on Sandoz AG's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,227,938 | Pharmaceutical Composition Containing Crystalline Sorafenib Tosylate In force · High confidence | Sandoz AG | In force | High confidence | |
| US 11,446,381 | Stable Aqueous Formulation for Growth Hormone In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,867,829 | Stable pharmaceutical composition containing 8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof In force · High confidence | Sandoz AG | In force | High confidence | |
| US 9,499,504 | Novel Crystalline Form of Vortioxetine Hydrobromide In force · High confidence | Sandoz AG | In force | High confidence | |
| US RE47,787 | Process for Preparing Ceftaroline Fosamil In force · Low confidence | Sandoz AG | In force | Low confidence | |
| US 9,677,107 | Method for Producing a Recombinant Protein of Interest by Using the Npro Technology In force · High confidence | Sandoz AG and Boehringer Ingelheim RCV GmbH & Co. KG | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.